Methemoglobinemia from dental drugs: the warning now printed on every local anesthetic label, and what it tells you to do

What it says#

This entry reports what the manufacturers' labels say. The treating dentist decides what to do for the patient in front of them, and a label warning is not a substitute for a call to emergency services when a patient turns gray in the chair.

Which dental drugs carry the risk. Prilocaine sits at the top because its label goes furthest: 4% Citanest Plain Dental and 4% Citanest Forte DENTAL are "contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia." The mechanism is named in the label's clinical pharmacology: prilocaine is split at the amide linkage to o-toluidine, and "O-toluidine has been found to produce methemoglobin, both in vitro and in vivo."

Benzocaine is the other agent a dentist thinks of first, and its risk is on the over-the-counter Drug Facts panel rather than in a prescribing insert. HurriCaine benzocaine 20% gel reads: "Methemoglobinemia warning: Use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount of oxygen carried in blood. This can occur even if you have used this product before." The same panel says do not use for teething and do not use in children under 2 years of age. The FDA's 2018 action that produced that language is covered in this directory at the entry fda-benzocaine-teething-warning-2018.

Articaine carries the risk in its own words, at section 5.4 of the ARTICADENT label, in the standardized class wording. So do lidocaine, mepivacaine and bupivacaine. The mepivacaine labels are the most vivid: Polocaine and Scandonest both say the drug, along with other local anesthetics, "is capable of producing this condition," and the Carbocaine label lists "cyanosis of the nail beds and lips, fatigue and weakness" as the clinical signs. The point worth internalizing is that after the FDA's 2018 class action there is no longer a dental local anesthetic without this warning; prilocaine and benzocaine are higher-profile, not uniquely implicated.

Who is more susceptible. The wording is identical across the labels: "Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended."

The signs, and the timing. "Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood." The mepivacaine labels extend that to "cyanosis of the skin, nail beds and lips, and/or abnormal coloration of the blood, fatigue and weakness." The patient-facing list every one of these labels asks you to give the patient is: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

The prilocaine label adds the numbers. "While methemoglobin values of less than 20% do not generally produce any clinical symptoms, the appearance of cyanosis at 2 to 4 hours following administration should be evaluated in terms of the general health status of the patient." That delay is the dangerous part in a dental office, because the patient is usually gone by then.

Management as the labels state it. "Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death." The steps: discontinue the drug and any other oxidizing agents; depending on severity, supportive care, meaning oxygen therapy and hydration; and for a more severe clinical presentation, methylene blue, exchange transfusion, or hyperbaric oxygen. Both the prilocaine and mepivacaine labels give the dose: "methemoglobinemia can be reversed when indicated by intravenous administration of methylene blue at a dosage of 1 to 2 mg/kg given over a five minute period." The Polocaine and Scandonest wording sequences it: if methemoglobinemia does not respond to administration of oxygen, a more severe presentation may require methylene blue, exchange transfusion or hyperbaric oxygen.

The other drugs on the list. The labels print a table, "Examples of drugs associated with methemoglobinemia," which names nitrates and nitrites (nitric oxide, nitroglycerin, nitroprusside and nitrous oxide); local anesthetics (articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine); antineoplastic agents (cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase); antibiotics (dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides); antimalarials (chloroquine, primaquine); anticonvulsants (phenobarbital, phenytoin, sodium valproate); and other drugs (acetaminophen, metoclopramide, quinine, sulfasalazine). Nitrous oxide on that list is worth a second look, given how routinely it runs alongside a topical and two cartridges.

Who it applies to#

Everyone in the operatory. The dentist choosing the agent, the hygienist placing a topical before scaling, the assistant giving the post-operative instructions, and the front desk taking the call three hours later from a patient who says they feel short of breath and look gray.

The labels single out a narrow set of higher-risk patients, and two of them are findable in a medical history: G6PD deficiency and a known congenital or idiopathic methemoglobinemia. Cardiac or pulmonary compromise is a judgment call, and infants under 6 months is a category most dental offices never see but every office with a benzocaine tube should know about.

The prilocaine contraindication is the only absolute in this entry. Everything else is a warning with monitoring attached.

What changed#

Before 2018, methemoglobinemia language on local anesthetic labels was uneven: prilocaine and benzocaine carried it, and others did not. The FDA's May 2018 Drug Safety Communication required a standardized warning across the prescription local anesthetics and named the class: articaine, bupivacaine, chloroprocaine, lidocaine, mepivacaine, prilocaine, ropivacaine and tetracaine. The dental cartridge labels read for this entry all now carry that wording, along with the identical patient-counseling sentence and the same table of associated drugs.

What has not changed is the prilocaine contraindication, which predates the class action, and the methylene blue dose, which has been on these labels for decades.

Where the source is#

All quoted language comes from FDA-approved labeling read on DailyMed for this entry. The link under the title opens the 4% Citanest Plain Dental label, which carries the contraindication, the o-toluidine mechanism, the drug table and the methylene blue dose. The downloads open ARTICADENT, Polocaine DENTAL, HurriCaine benzocaine 20% gel, Cetacaine and Oraqix. The FDA's May 2018 action that produced the class warning, and the archived FDA documents behind it, are carried in this directory's entry at slug fda-benzocaine-teething-warning-2018. Versions read: Citanest Plain Dental published November 15, 2021; Citanest Forte DENTAL and ARTICADENT published March 4, 2024; Polocaine DENTAL and Carbocaine published February 23, 2024; Scandonest 3% Plain published June 2, 2025; 2% Xylocaine DENTAL published August 17, 2026; Oraqix published April 22, 2026; Cetacaine Spray and Liquid published January 16, 2025; HurriCaine gel published March 16, 2026. The FDA's own 2018 Drug Safety Communication page refused automated access in this session, so the dated timeline entries for FDA actions are reported from the directory's existing benzocaine entry and the archived news release rather than re-read here.